|
1
|
Zińczuk J, Zaręba K, Romaniuk W, Kamińska
D, Nizioł M, Baszun M, Kędra B, Guzińska-Ustymowicz K and
Pryczynicz A: Expression of chosen carcinoembryonic-related cell
adhesion molecules in pancreatic intraepithelial neoplasia (PanIN)
associated with chronic pancreatitis and pancreatic ductal
adenocarcinoma (PDAC). Int J Med Sci. 16:583–592. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hu JX, Zhao CF, Chen WB, Liu QC, Li QW,
Lin YY and Gao F: Pancreatic cancer: A review of epidemiology,
trend, and risk factors. World J Gastroenterol. 27:4298–4321.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pereira SP, Oldfield L, Ney A, Hart PA,
Keane MG, Pandol SJ, Li D, Greenhalf W, Jeon CY, Koay EJ, et al:
Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol.
5:698–710. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kleeff J, Korc M, Apte M, La Vecchia C,
Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH
and Neoptolemos JP: Pancreatic cancer. Nat Rev Dis Primers 2:
16022. 2016.
|
|
5
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Schober M, Jesenofsky R, Faissner R,
Weidenauer C, Hagmann W, Michl P, Heuchel RL, Haas SL and Löhr JM:
Desmoplasia and chemoresistance in pancreatic cancer. Cancers
(Basel). 6:2137–2154. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Azizian A, Rühlmann F, Krause T, Bernhardt
M, Jo P, König A, Kleiß M, Leha A, Ghadimi M and Gaedcke J: CA19-9
for detecting recurrence of pancreatic cancer. Sci Rep.
10(1332)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Goh SK, Gold G, Christophi C and
Muralidharan V: Serum carbohydrate antigen 19-9 in pancreatic
adenocarcinoma: A mini review for surgeons. ANZ J Surg. 87:987–992.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Moffitt RA, Marayati R, Flate EL, Volmar
KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung
AH, et al: Virtual microdissection identifies distinct tumor- and
stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat
Genet. 47:1168–1178. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tanase CP, Neagu M, Albulescu R and
Hinescu ME: Advances in pancreatic cancer detection. Adv Clin Chem.
51:145–180. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang D, Li Y, Ge H, Ghadban T, Reeh M and
Güngör C: The extracellular matrix: A key accomplice of cancer stem
cell migration, metastasis formation, and drug resistance in PDAC.
Cancers (Basel). 14(3998)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Janiszewska M, Primi MC and Izard T: Cell
adhesion in cancer: Beyond the migration of single cells. J Biol
Chem. 295:2495–2505. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cox TR: The matrix in cancer. Nat Rev
Cancer. 21:217–238. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Pandey R, Zhou M, Islam S, Chen B, Barker
NK, Langlais P, Srivastava A, Luo M, Cooke LS, Weterings E and
Mahadevan D: Carcinoembryonic antigen cell adhesion molecule 6
(CEACAM6) in pancreatic ductal adenocarcinoma (PDA): An integrative
analysis of a novel therapeutic target. Sci Rep.
9(18347)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Han ZW, Lyv ZW, Cui B, Wang YY, Cheng JT,
Zhang Y, Cai WQ, Zhou Y, Ma ZW, Wang XW, et al: The old CEACAMs
find their new role in tumor immunotherapy. Invest New Drugs.
38:1888–1898. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Johnson B and Mahadevan D: Emerging role
and targeting of carcinoembryonic antigen-related cell adhesion
molecule 6 (CEACAM6) in human malignancies. Clin Cancer Drugs.
2:100–111. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Duxbury MS, Ito H, Ashley SW and Whang EE:
c-Src-dependent cross-talk between CEACAM6 and alphavbeta3 integrin
enhances pancreatic adenocarcinoma cell adhesion to extracellular
matrix components. Biochem Biophys Res Commun. 317:133–141.
2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hatakeyama K, Wakabayashi-Nakao K, Ohshima
K, Sakura N, Yamaguchi K and Mochizuki T: Novel protein isoforms of
carcinoembryonic antigen are secreted from pancreatic, gastric and
colorectal cancer cells. BMC Res Notes. 6(381)2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Blumenthal RD, Leon E, Hansen HJ and
Goldenberg DM: Expression patterns of CEACAM5 and CEACAM6 in
primary and metastatic cancers. BMC Cancer. 7(2)2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang Y, Zang M, Li J, Ji J, Zhang J, Liu
X, Qu Y, Su L, Li C, Yu Y, et al: CEACAM6 promotes tumor migration,
invasion, and metastasis in gastric cancer. Acta Biochim Biophys
Sin (Shanghai). 46:283–290. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tchoupa AK, Schuhmacher T and Hauck CR:
Signaling by epithelial members of the CEACAM family-mucosal
docking sites for pathogenic bacteria. Cell Commun Signal.
12(27)2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wu G, Wang D, Xiong F, Wang Q, Liu W, Chen
J and Chen Y: The emerging roles of CEACAM6 in human cancer
(Review). Int J Oncol. 64(27)2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Valdembri D and Serini G: The roles of
integrins in cancer. Fac Rev. 10(45)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kuespert K, Pils S and Hauck CR: CEACAMs:
Their role in physiology and pathophysiology. Curr Opin Cell Biol.
18:565–571. 2006.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Schölzel S, Zimmermann W, Schwarzkopf G,
Grunert F, Rogaczewski B and Thompson J: Carcinoembryonic antigen
family members CEACAM6 and CEACAM7 are differentially expressed in
normal tissues and oppositely deregulated in hyperplastic
colorectal polyps and early adenomas. Am J Pathol. 156:595–605.
2000.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zimmermann W and Kammerer R:
Carcinoembryonic antigen. Tumor-Associated Antigens:
Identification, Characterization, and Clinical Applications,
pp201-218, 2009.
|
|
27
|
Gold P and Freedman SO: Specific
carcinoembryonic antigens of the human digestive system. J Exp Med.
122:467–481. 1965.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Gray-Owen SD and Blumberg RS: CEACAM1:
Contact-dependent control of immunity. Nat Rev Immunol. 6:433–446.
2006.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Bonsor DA, Günther S, Beadenkopf R,
Beckett D and Sundberg EJ: Diverse oligomeric states of CEACAM IgV
domains. Proc Natl Acad Sci USA. 112:13561–13566. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Noworolska A, Harłozińska A, Richter R and
Brodzka W: Non-specific cross-reacting antigen (NCA) in individual
maturation stages of myelocytic cell series. Br J Cancer.
51:371–377. 1985.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hanenberg H, Baumann M, Quentin I, Nagel
G, Grosse-Wilde H, von Kleist S, Göbel U, Burdach S and Grunert F:
Expression of the CEA gene family members NCA-50/90 and NCA-160
(CD66) in childhood acute lymphoblastic leukemias (ALLs) and in
cell lines of B-cell origin. Leukemia. 8:2127–2133. 1994.PubMed/NCBI
|
|
32
|
Chan CHF and Stanners CP: Novel mouse
model for carcinoembryonic antigen-based therapy. Mol Ther.
9:775–785. 2004.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Blumenthal RD, Hansen HJ and Goldenberg
DM: Inhibition of adhesion, invasion, and metastasis by antibodies
targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen).
Cancer Res. 65:8809–8817. 2005.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Skubitz KM: The role of CEACAM s in
neutrophil function. Eur J Clin Invest. 54 (Suppl
2)(e14349)2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Schumann D, Huang J, Clarke PE, Kirshner
J, Tsai SW, Schumaker VN and Shively JE: Characterization of
recombinant soluble carcinoembryonic antigen cell adhesion molecule
1. Biochem Biophys Res Commun. 318:227–233. 2004.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lu R, Pan H and Shively JE: CEACAM1
negatively regulates IL-1β production in LPS activated neutrophils
by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex. PLoS Pathog.
8(e1002597)2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Klaile E, Vorontsova O, Sigmundsson K,
Müller MM, Singer BB, Ofverstedt LG, Svensson S, Skoglund U and
Obrink B: The CEACAM1 N-terminal Ig domain mediates cis- and
trans-binding and is essential for allosteric rearrangements of
CEACAM1 microclusters. J Cell Biol. 187:553–567. 2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Markel G, Achdout H, Katz G, Ling KL,
Salio M, Gruda R, Gazit R, Mizrahi S, Hanna J, Gonen-Gross T, et
al: Biological function of the soluble CEACAM1 protein and
implications in TAP2-deficient patients. Eur J Immunol.
34:2138–2148. 2004.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kiriyama S, Yokoyama S, Ueno M, Hayami S,
Ieda J, Yamamoto N, Yamaguchi S, Mitani Y, Nakamura Y, Tani M, et
al: CEACAM1 long cytoplasmic domain isoform is associated with
invasion and recurrence of hepatocellular carcinoma. Ann Surg
Oncol. 21 (Suppl 4):S505–S514. 2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Shamsuddin SHB: Biosensors for detection
of colorectal cancer. University of Leeds, 2018.
|
|
41
|
Chan CHF and Stanners CP: Recent advances
in the tumour biology of the GPI-anchored carcinoembryonic antigen
family members CEACAM5 and CEACAM6. Curr Oncol. 14:70–73.
2007.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chiang WF, Cheng TM, Chang CC, Pan SH,
Changou CA, Chang TH, Lee KH, Wu SY, Chen YF, Chuang KH, et al:
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)
promotes EGF receptor signaling of oral squamous cell carcinoma
metastasis via the complex N-glycosylation. Oncogene. 37:116–127.
2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Swords DS, Firpo MA, Scaife CL and
Mulvihill SJ: Biomarkers in pancreatic adenocarcinoma: Current
perspectives. Onco Targets Ther. 9:7459–7467. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Thomas J, Klebanov A, John S, Miller LS,
Vegesna A, Amdur RL, Bhowmick K and Mishra L: CEACAMS 1, 5, and 6
in disease and cancer: Interactions with pathogens. Genes Cancer.
14:12–29. 2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ordonez C, Zhai AB, Camacho-Leal P,
Demarte L, Fan MM and Stanners CP: GPI-anchored CEA family
glycoproteins CEA and CEACAM6 mediate their biological effects
through enhanced integrin alpha5beta1-fibronectin interaction. J
Cell Physiol. 210:757–765. 2007.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kelleher M, Singh R, O'Driscoll CM and
Melgar S: Carcinoembryonic antigen (CEACAM) family members and
inflammatory bowel disease. Cytokine Growth Factor Rev. 47:21–31.
2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Al-Khinji A: 122 CEACAM6 molecules mediate
cell adhesion and signaling by modifying integrins in human solid
tumors. J Clin Transl Sci. 9 (Suppl 1)(S35)2025.
|
|
48
|
Zhao D, Cai F, Liu X, Li T, Zhao E, Wang X
and Zheng Z: CEACAM6 expression and function in tumor biology: A
comprehensive review. Discov Oncol. 15(186)2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Dhasmana A, Dhasmana S, Kotnala S, Laskar
P, Khan S, Haque S, Jaggi M, Yallapu MM and Chauhan SC: CEACAM7
expression contributes to early events of pancreatic cancer. J Adv
Res. 55:61–72. 2024.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Raj D, Nikolaidi M, Garces I, Lorizio D,
Castro NM, Caiafa SG, Moore K, Brown NF, Kocher HM, Duan X, et al:
CEACAM7 is an effective target for CAR T-cell therapy of pancreatic
ductal adenocarcinoma. Clin Cancer Res. 27:1538–1552.
2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Pavlopoulou A and Scorilas A: A
comprehensive phylogenetic and structural analysis of the
carcinoembryonic antigen (CEA) gene family. Genome Biol Evol.
6:1314–1326. 2014.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Rizeq B, Zakaria Z and Ouhtit A: Towards
understanding the mechanisms of actions of carcinoembryonic
antigen-related cell adhesion molecule 6 in cancer progression.
Cancer Sci. 109:33–42. 2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Beauchemin N and Arabzadeh A:
Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs)
in cancer progression and metastasis. Cancer Metastasis Rev.
32:643–671. 2013.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Zhao L, Li T, Zhou Y, Wang P and Luo L:
Monoclonal antibody targeting CEACAM1 enhanced the response to
anti-PD1 immunotherapy in non-small cell lung cancer. Int
Immunopharmacol. 143(113395)2024.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Singer BB: CEACAMs. In Encyclopedia of
Signaling Molecules. Springer, pp1-9, 2016.
|
|
56
|
Tilki D, Singer BB, Shariat SF, Behrend A,
Fernando M, Irmak S, Buchner A, Hooper AT, Stief CG, Reich O and
Ergün S: CEACAM1: A novel urinary marker for bladder cancer
detection. Eur Urol. 57:648–654. 2010.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Simeone DM, Ji B, Banerjee M, Arumugam T,
Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran
V and Logsdon CD: CEACAM1, a novel serum biomarker for pancreatic
cancer. Pancreas. 34:436–443. 2007.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Ji B, Simeone D, Ramachandran V, Arumugam
T, Hanash S, Giordano T, Greenson J, Taylor J and Logsdon CD:
CEACAM1 is a biomarker for pancreatic cancer. Pancreas. 29:336–337.
2004.
|
|
59
|
Shi JF, Xu SX, He P and Xi ZH: Expression
of carcinoembryonic antigen-related cell adhesion molecule
1(CEACAM1) and its correlation with angiogenesis in gastric cancer.
Pathol Res Pract. 210:473–476. 2014.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kurlinkus B, Ger M, Kaupinis A, Jasiunas
E, Valius M and Sileikis A: CEACAM6's role as a chemoresistance and
prognostic biomarker for pancreatic cancer: A comparison of
CEACAM6's diagnostic and prognostic capabilities with those of
CA19-9 and CEA. Life (Basel). 11(542)2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Qian W, Huang P, Liang X, Chen Y and Guan
B: High expression of carcinoembryonic antigen-associated cell
adhesion molecule 1 is associated with microangiogenesis in
esophageal squamous cell carcinoma. Transl Cancer Res. 9:4762–4769.
2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Zhou M, Jin Z, Liu Y, He Y, Du Y, Yang C,
Wang Y, Hu J, Cui L, Gao F and Cao M: Up-regulation of
carcinoembryonic antigen-related cell adhesion molecule 1 in
gastrointestinal cancer and its clinical relevance. Acta Biochim
Biophys Sin (Shanghai). 49:737–743. 2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Kim WM, Huang YH, Gandhi A and Blumberg
RS: CEACAM1 structure and function in immunity and its therapeutic
implications. Semin Immunol. 42(101296)2019.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Lu R, Kujawski M, Pan H and Shively JE:
Tumor angiogenesis mediated by myeloid cells is negatively
regulated by CEACAM1. Cancer Res. 72:2239–2250. 2012.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Dong J, Wang B, Wang D, Ni J, Bu T, Wang
H, Nayak B, Wang B, Dong X and Zhang Y: Abstract 2732: NB203: A
novel therapeutic bispecific antibody targeting CEACAM1/VEGF for
tumor immunity and angiogenesis modulation in the tumor
microenvironment. Cancer Res. 84 (6 Suppl)(S2732)2024.
|
|
66
|
Zuo J, Wang Y, Chen Z, Li H, Yang Y, Zhang
Y, Zhang L and Chen J: Development of CEACAM1-specific CAR-T cells
for the treatment of malignant melanoma. Oncol Rep. 49(72)2023.
|
|
67
|
Huang Y, Wang H, Lichtenberger J, Zhang J,
Kappes J and Wu Y: CEACAM1 as a potential therapeutic target in
melanoma and other malignancies. Front Oncol. 9(1072)2019.
|
|
68
|
Partyka K, Maupin KA, Brand RE and Haab
BB: Diverse monoclonal antibodies against the CA 19-9 antigen show
variation in binding specificity with consequences for clinical
interpretation. Proteomics. 12:2212–2220. 2012.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Yang L, Liu Y, Zhang B, Yu M, Huang F,
Zeng J, Lu Y and Yang C: CEACAM1 is a prognostic biomarker and
correlated with immune cell infiltration in clear cell renal cell
carcinoma. Dis Markers. 2023(3606362)2023.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Ligorio M, Sil S, Malagon-Lopez J, Nieman
LT, Misale S, Di Pilato M, Ebright RY, Karabacak MN, Kulkarni AS,
Liu A, et al: Stromal microenvironment shapes the intratumoral
architecture of pancreatic cancer. Cell. 178:160–175.e27.
2019.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Gisina A, Novikova S, Kim Y, Sidorov D,
Bykasov S, Volchenko N, Kaprin A, Zgoda V, Yarygin K and Lupatov A:
CEACAM5 overexpression is a reliable characteristic of
CD133-positive colorectal cancer stem cells. Cancer Biomark.
32:85–98. 2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Chen J, Li Q, An Y, Lv N, Xue X, Wei J,
Jiang K, Wu J, Gao W, Qian Z, et al: CEACAM6 induces
epithelial-mesenchymal transition and mediates invasion and
metastasis in pancreatic cancer. Int J Oncol. 43:877–885.
2013.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Witzens-Harig M, Hose D, Jünger S,
Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H,
Brackertz B, Rème T, et al: Tumor cells in multiple myeloma
patients inhibit myeloma-reactive T cells through carcinoembryonic
antigen-related cell adhesion molecule-6. Blood. 121:4493–4503.
2013.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Kemper M, Schiecke A, Maar H, Nikulin S,
Poloznikov A, Galatenko V, Tachezy M, Gebauer F, Lange T, Riecken
K, et al: Integrin alpha-V is an important driver in pancreatic
adenocarcinoma progression. J Exp Clin Cancer Res.
40(214)2021.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Mahadevan D, Pandey R, Chen Y, Essif J and
Al-Khinji A: Oncogenic roles of CEACAM6 in pancreatic ductal
adenocarcinoma. J Clin Oncol. 38 (15 Suppl)(e16744)2020.
|
|
76
|
Kim H, Woo CG, Son SM, Lee YP, Kim HK,
Yang Y, Kwon J, Lee KH, Lee HC, Lee OJ and Han HS: Targeted
suppression of CEACAM6 via pHLIP-delivered rnas in pancreatic
ductal adenocarcinoma. Medicina (Kaunas). 61(598)2025.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Wu J, Pan TH, Xu S, Jia LT, Zhu LL, Mao
JS, Zhu YL and Cai JT: The virus-induced protein APOBEC3G inhibits
anoikis by activation of Akt kinase in pancreatic cancer cells. Sci
Rep. 5(12230)2015.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Zang M, Zhang Y, Zhang B, Hu L, Li J, Fan
Z, Wang H, Su L, Zhu Z, Li C, et al: CEACAM6 promotes tumor
angiogenesis and vasculogenic mimicry in gastric cancer via FAK
signaling. Biochim Biophys Acta. 1852:1020–1028. 2015.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Niu G, Murad YM, Gao H, Hu S, Guo N,
Jacobson O, Nguyen TD, Zhang J and Chen X: Molecular targeting of
CEACAM6 using antibody probes of different sizes. J Control
Release. 161:18–24. 2012.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Ma RX, Wei JR and Hu YW: Characteristics
of carcinoembryonic antigen related cell adhesion molecules and
their relationship to cancer. Mol Cancer Ther. 23:939–948.
2024.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Te Molder L, Kreft M, Heemskerk N,
Schuring J, de Pereda JM, Wilhelmsen K and Sonnenberg A:
EGFR-dependent tyrosine phosphorylation of integrin β4 is not
required for downstream signaling events in cancer cell lines. Sci
Rep. 11(8675)2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Du H, Li Y, Sun R, Yuan Y, Sun S and Zhang
Y: CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and
is regulated by microRNA-146a and microRNA-26a. Thorac Cancer.
11:2473–2482. 2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Ambrosi C, Scribano D, Sarshar M, Zagaglia
C, Singer BB and Palamara AT: Acinetobacter baumannii targets human
carcinoembryonic antigen-related cell adhesion molecules (CEACAMs)
for invasion of pneumocytes. mSystems. 5:e00604–20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Al Khinji A: Carcinoembryonic antigen cell
adhesion molecule 6 enhances invasiveness and immune suppression in
pancreatic adenocarcinoma, 2022.
|
|
86
|
Chen Z, Chen L, Qiao SW, Nagaishi T and
Blumberg RS: Carcinoembryonic antigen-related cell adhesion
molecule 1 inhibits proximal TCR signaling by targeting ZAP-70. J
Immunol. 180:6085–6093. 2008.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Götz L, Rueckschloss U, Ergün S and
Kleefeldt F: CEACAM1 in vascular homeostasis and inflammation. Eur
J Clin Invest. 54 (Suppl 2)(e14345)2024.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Lee EH, Kim HT, Chun SY, Chung JW, Choi
SH, Lee JN, Kim BS, Yoo ES, Kwon TG, Kim TH and Ha YS: Role of the
JNK pathway in bladder cancer. Onco Targets Ther. 15:963–971.
2022.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Liao J, Chen R, Lin B, Deng R, Liang Y,
Zeng J, Ma S and Qiu X: Cross-Talk between the TGF-β and cell
adhesion signaling pathways in cancer. Int J Med Sci. 21:1307–1320.
2024.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Kim EY, Cha YJ, Jeong S and Chang YS:
Overexpression of CEACAM6 activates Src-FAK signaling and inhibits
anoikis, through homophilic interactions in lung adenocarcinomas.
Transl Oncol. 20(101402)2022.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Do CTP, Prochnau JY, Dominguez A, Wang P
and Rao MK: The road ahead in pancreatic cancer: Emerging trends
and therapeutic prospects. Biomedicines. 12(1979)2024.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Chen K, Li Y, Guo Z, Zeng Y and Zhang W:
Identification of CEACAM6 as a biomarker for circulating tumor
cells and its clinical significance in pancreatic cancer. Front
Oncol. 11(659133)2021.
|
|
93
|
Primac I, Maquoi E, Blacher S, Heljasvaara
R, Van Deun J, Smeland HY, Canale A, Louis T, Stuhr L, Sounni NE,
et al: Stromal integrin α11 regulates PDGFR-β signaling and
promotes breast cancer progression. J Clin Invest. 129:4609–4628.
2019.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Hartupee C, Nagalo BM, Chabu CY, Tesfay
MZ, Coleman-Barnett J, West JT and Moaven O: Pancreatic cancer
tumor microenvironment is a major therapeutic barrier and target.
Front Immunol. 15(1287459)2024.PubMed/NCBI View Article : Google Scholar
|
|
95
|
González-Amaro R and Sánchez-Madrid F:
Cell adhesion molecules: Selectins and integrins. rit Rev Immunol.
19:389–429. 1999.PubMed/NCBI
|
|
96
|
Aplin AE, Howe A, Alahari SK and Juliano
RL: Signal transduction and signal modulation by cell adhesion
receptors: The role of integrins, cadherins, immunoglobulin-cell
adhesion molecules, and selectins. Pharmacol Rev. 50:197–263.
1998.PubMed/NCBI
|
|
97
|
Gao J and Nakamura F: Actin-associated
proteins and small molecules targeting the actin cytoskeleton. Int
J Mol Sci. 23(2118)2022.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Nishiuchi R, Takagi J, Hayashi M, Ido H,
Yagi Y, Sanzen N, Tsuji T, Yamada M and Sekiguchi K: Ligand-binding
specificities of laminin-binding integrins: A comprehensive survey
of laminin-integrin interactions using recombinant alpha3beta1,
alpha6beta1, alpha7beta1 and alpha6beta4 integrins. Matrix Biol.
25:189–197. 2006.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Brassart-Pasco S, Brézillon S, Brassart B,
Ramont L, Oudart JB and Monboisse JC: Tumor microenvironment:
Extracellular matrix alterations influence tumor progression. Front
Oncol. 10(397)2020.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Giancotti FG and Tarone G: Positional
control of cell fate through joint integrin/receptor protein kinase
signaling. Annu Rev Cell Dev Biol. 19:173–206. 2003.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Ivaska J and Heino J: Cooperation between
integrins and growth factor receptors in signaling and endocytosis.
Annu Rev Cell Dev Biol. 27:291–320. 2011.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Cabodi S, Moro L, Bergatto E, Boeri Erba
E, Di Stefano P, Turco E, Tarone G and Defilippi P: Integrin
regulation of epidermal growth factor (EGF) receptor and of
EGF-dependent responses. Biochem Soc Trans. 32:438–442.
2004.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Hurtado de Mendoza T, Mose ES, Botta GP,
Braun GB, Kotamraju VR, French RP, Suzuki K, Miyamura N, Teesalu T,
Ruoslahti E, et al: Tumor-penetrating therapy for β5 integrin-rich
pancreas cancer. Nat Commun. 12(1541)2021.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Tsai YT, Wu AC, Yang WB, Kao TJ, Chuang
JY, Chang WC and Hsu TI: ANGPTL4 induces TMZ resistance of
glioblastoma by promoting cancer stemness enrichment via the
EGFR/AKT/4E-BP1 cascade. Int J Mol Sci. 20(5625)2019.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Masugi Y, Yamazaki K, Emoto K, Effendi K,
Tsujikawa H, Kitago M, Itano O, Kitagawa Y and Sakamoto M:
Upregulation of integrin β4 promotes epithelial-mesenchymal
transition and is a novel prognostic marker in pancreatic ductal
adenocarcinoma. Lab Invest. 95:308–319. 2015.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Weinel RJ, Rosendahl A, Pinschmidt E,
Kisker O, Simon B and Santoso S: The alpha 6-integrin receptor in
pancreatic carcinoma. Gastroenterology. 108:523–532.
1995.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Meng X, Liu P, Wu Y, Liu X, Huang Y, Yu B,
Han J, Jin H and Tan X: Integrin beta 4 (ITGB4) and its
tyrosine-1510 phosphorylation promote pancreatic tumorigenesis and
regulate the MEK1-ERK1/2 signaling pathway. Bosn J Basic Med Sci.
20:106–116. 2020.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Jeong BY, Cho KH, Jeong KJ, Park YY, Kim
JM, Rha SY, Park CG, Mills GB, Cheong JH and Lee HY: Rab25 augments
cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail
signaling axis and expression of fascin. Exp Mol Med.
50(e435)2018.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Schinke H, Shi E, Lin Z, Quadt T, Kranz G,
Zhou J, Wang H, Hess J, Heuer S, Belka C, et al: A transcriptomic
map of EGFR-induced epithelial-to-mesenchymal transition identifies
prognostic and therapeutic targets for head and neck cancer. Mol
Cancer. 21(178)2022.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Calinescu A, Turcu G, Nedelcu RI, Brinzea
A, Hodorogea A, Antohe M, Diaconu C, Bleotu C, Pirici D, Jilaveanu
LB, et al: On the dual role of carcinoembryonic antigen-related
cell adhesion molecule 1 (CEACAM1) in human malignancies. J Immunol
Res. 2018(7169081)2018.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Cavaco ACM, Rezaei M, Caliandro MF, Lima
AM, Stehling M, Dhayat SA, Haier J, Brakebusch C and Eble JA: The
interaction between laminin-332 and α3β1 integrin determines
differentiation and maintenance of CAFs, and supports invasion of
pancreatic duct adenocarcinoma cells. Cancers (Basel).
11(14)2018.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Aziz MH, Saida L, van Eijck CHJ and
Mustafa DAM: Overexpression of the adhesion signaling pathway is
linked to short-term survival in pancreatic ductal adenocarcinoma.
Pancreatology. 24:62–65. 2024.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Calderwood DA: Talin controls integrin
activation. Biochem Soc Trans. 32:434–437. 2004.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Moser M, Legate KR, Zent R and Fässler R:
The tail of integrins, talin, and kindlins. Science. 324:895–899.
2009.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Baig MMFA, Zhang QW, Younis MR and Xia XH:
A DNA nanodevice simultaneously activating the EGFR and integrin
for enhancing cytoskeletal activity and cancer cell treatment. Nano
Lett. 19:7503–7513. 2019.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Liu M, Zhang Y, Yang J, Cui X, Zhou Z,
Zhan H, Ding K, Tian X, Yang Z, Fung KMA, et al: ZIP4 increases
expression of transcription factor ZEB1 to promote Integrin α3β1
signaling and inhibit expression of the gemcitabine transporter
ENT1 in pancreatic cancer cells. Gastroenterology. 158:679–692.e1.
2020.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Yu CH, Rafiq NB, Cao F, Zhou Y,
Krishnasamy A, Biswas KH, Ravasio A, Chen Z, Wang YH, Kawauchi K,
et al: Integrin-beta3 clusters recruit clathrin-mediated endocytic
machinery in the absence of traction force. Nat Commun.
6(8672)2015.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Ye F, Petrich BG, Anekal P, Lefort CT,
Kasirer-Friede A, Shattil SJ, Ruppert R, Moser M, Fässler R and
Ginsberg MH: The mechanism of kindlin-mediated activation of
integrin αIIbβ3. Curr Biol. 23:2288–2295. 2013.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Baschieri F, Dayot S, Elkhatib N, Ly N,
Capmany A, Schauer K, Betz T, Vignjevic DM, Poincloux R and
Montagnac G: Frustrated endocytosis controls
contractility-independent mechanotransduction at clathrin-coated
structures. Nat Commun. 9(3825)2018.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Franco-Barraza J, Francescone R, Luong T,
Shah N, Madhani R, Cukierman G, Dulaimi E, Devarajan K, Egleston
BL, Nicolas E, et al: Matrix-regulated integrin
αvβ5 maintains
α5β1-dependent desmoplastic traits prognostic
of neoplastic recurrence. Elife. 6(e20600)2017.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Harryman WL, Marr KD, Nagle RB and Cress
AE: Integrins and epithelial-mesenchymal cooperation in the tumor
microenvironment of muscle-invasive lethal cancers. Front Cell Dev
Biol. 10(837585)2022.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Myo Min KK, Ffrench CB, Jessup CF,
Shepherdson M, Barreto SG and Bonder CS: Overcoming the fibrotic
fortress in pancreatic ductal adenocarcinoma: Challenges and
opportunities. Cancers (Basel). 15(2354)2023.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Belhabib I, Zaghdoudi S, Lac C, Bousquet C
and Jean C: Extracellular matrices and cancer-associated
fibroblasts: Targets for cancer diagnosis and therapy? Cancers
(Basel). 13(3466)2021.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Schaffner F, Ray AM and Dontenwill M:
Integrin α5β1, the fibronectin receptor, as a pertinent therapeutic
target in solid tumors. Cancers (Basel). 5:27–47. 2013.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Gan L, Meng J, Xu M, Liu M, Qi Y, Tan C,
Wang Y, Zhang P, Weng W, Sheng W, et al: Extracellular matrix
protein 1 promotes cell metastasis and glucose metabolism by
inducing integrin β4/FAK/SOX2/HIF-1α signaling pathway in gastric
cancer. Oncogene. 37:744–755. 2018.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Yang H, Xu Z, Peng Y, Wang J and Xiang Y:
Integrin β4 as a potential diagnostic and therapeutic tumor marker.
Biomolecules. 11(1197)2021.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Liu F, Wu Q, Dong Z and Liu K: Integrins
in cancer: Emerging mechanisms and therapeutic opportunities.
Pharmacol Ther. 247(108458)2023.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Liu C, Wang M, Lv H, Liu B, Ya X, Zhao W
and Wang W: CEACAM6 promotes cholangiocarcinoma migration and
invasion by inducing epithelial-mesenchymal transition through
inhibition of the SRC/PI3K/AKT signaling pathway. Oncol Lett.
23(39)2022.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Schnittert J, Bansal R, Mardhian DF, van
Baarlen J, Östman A and Prakash J: Integrin α11 in pancreatic
stellate cells regulates tumor-stroma interactions in pancreatic
ductal adenocarcinoma. Cancers. 11(14)2019.DOI:
10.3390/cancers11010014.
|
|
130
|
Chen X, Liu P, Wu Y, Liu X, Huang Y, Yu B,
Han J, Jin H and Tan X: Integrin α3 promotes pancreatic cancer cell
invasion by activating EGFR signaling and cytoskeletal remodeling.
Bosn J Basic Med Sci. 22:106–114. 2022.DOI:
10.17305/bjbms.2022.6411.
|
|
131
|
Mia MM, Boersema M and Bank RA: αvβ1
Integrin-mediated activation of TGF-β controls αvβ6 integrin
expression to promote pancreatic carcinoma progression. J Pathol.
253:367–382. 2021.DOI: 10.1002/path.5597.
|
|
132
|
Kuninty PR, Bansal R, De Geus SWL,
Mardhian DF, Schnittert J, van Baarlen J, Storm G, Bijlsma MF, van
Laarhoven HW, Metselaar JM, et al: ITGA5 inhibition in pancreatic
stellate cells attenuates desmoplasia and potentiates efficacy of
chemotherapy in pancreatic cancer. Sci Adv.
5(eaax2770)2019.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Li X, Placencio V, Iturregui JM, Uwamariya
C, Sharif-Afshar AR, Koyama T, Hayward SW and Bhowmick NA: Prostate
fibroblast αvβ6 integrin expression drives prostate cancer
progression via epithelial-mesenchymal transition. Oncogene.
34:881–890. 2015.DOI: 10.1038/onc.2014.19.
|
|
134
|
Humphries JD, Chastney MR, Askari JA and
Humphries MJ: Signal transduction via integrin adhesion complexes.
Curr Opin Cell Biol. 56:14–21. 2019.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Zhu R, Ge J, Ma J and Zheng J:
Carcinoembryonic antigen related cell adhesion molecule 6 promotes
the proliferation and migration of renal cancer cells through the
ERK/AKT signaling pathway. Transl Androl Urol. 8:457–466.
2019.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Barnich N, Carvalho FA, Glasser AL, Darcha
C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P,
Colombel JF, et al: CEACAM6 acts as a receptor for
adherent-invasive E. coli, supporting ileal mucosa colonization in
Crohn disease. J Clin Invest. 117:1566–1574. 2007.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Fechter P, Cruz Da Silva E, Mercier MC,
Noulet F, Etienne-Seloum N, Guenot D, Lehmann M, Vauchelles R,
Martin S, Lelong-Rebel I, et al: RNA aptamers targeting integrin
α5β1 as probes for Cyto- and histofluorescence in glioblastoma. Mol
Ther Nucleic Acids. 17:63–77. 2019.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Schmitter T, Pils S, Weibel S, Agerer F,
Peterson L, Buntru A, Kopp K and Hauck CR: Opa proteins of
pathogenic neisseriae initiate Src kinase-dependent or lipid
raft-mediated uptake via distinct human carcinoembryonic
antigen-related cell adhesion molecule isoforms. Infect Immun.
75:4116–4126. 2007.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Zhang ZC, Zhao HF, Sun Z, Li Y, Zhong ML,
Wang BH and Jiang XZ: Tripartite motif-containing 9 promoted
proliferation and migration of bladder cancer cells through
CEACAM6-Smad2/3 axis. J Cell Commun Signal. 17:1323–1333.
2023.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Monkman JH, Thompson EW and Nagaraj SH:
Targeting epithelial mesenchymal plasticity in pancreatic cancer: A
compendium of preclinical discovery in a heterogeneous disease.
Cancers (Basel). 11(1745)2019.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Zhou R, Wu H, You H, Wang X, Yuan X, Sun
Z, Zhou D, Jiang Y and Shen Y: ESPN activates ZEB1-mediated EMT
through the PI3K/AKT/mTOR axis to promote osteosarcoma metastasis.
J Transl Med. 23(527)2025.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Rice AJ, Cortes E, Lachowski D, Cheung
BCH, Karim SA, Morton JP and Del Río Hernández A: Matrix stiffness
induces epithelial-mesenchymal transition and promotes
chemoresistance in pancreatic cancer cells. Oncogenesis.
6(e352)2017.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Debreli Coskun M, Sudha T, Bharali DJ,
Celikler S, Davis PJ and Mousa SA: αvβ3 integrin antagonists
enhance chemotherapy response in an orthotopic pancreatic cancer
model. Front Pharmacol. 11(95)2020.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Farhangnia P, Khorramdelazad H, Nickho H
and Delbandi AA: Current and future immunotherapeutic approaches in
pancreatic cancer treatment. J Hematol Oncol. 17(40)2024.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Cardenas KCA, Enos CW, Spear MR, Austin
DE, Almofeez R, Kortchak S, Pincus L, Guo HB, Dolezal S, Pierce JM,
et al: CT109-SN-38, a novel antibody-drug conjugate with dual
specificity for CEACAM5 and 6, elicits potent killing of pancreatic
cancer cells. Curr Cancer Drug Targets. 24:720–732. 2024.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Topalovski M and Brekken RA: Matrix
control of pancreatic cancer: New insights into fibronectin
signaling. Cancer Lett. 381:252–258. 2016.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Belvisi L, Riccioni T, Marcellini M, Vesci
L, Chiarucci I, Efrati D, Potenza D, Scolastico C, Manzoni L,
Lombardo K, et al: Biological and molecular properties of a new
alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther.
4:1670–1680. 2005.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Sherman MH and Beatty GL: Tumor
microenvironment in pancreatic cancer pathogenesis and therapeutic
resistance. Annu Rev Pathol. 18:123–148. 2023.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Palma AM, Vudatha V, Peixoto ML and Madan
E: Tumor heterogeneity: An oncogenic driver of PDAC progression and
therapy resistance under stress conditions. Adv Cancer Res.
159:203–249. 2023.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Singer BB, Scheffrahn I, Kammerer R,
Suttorp N, Ergun S and Slevogt H: Deregulation of the CEACAM
expression pattern causes undifferentiated cell growth in human
lung adenocarcinoma cells. PLoS One. 5(e8747)2010.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Ju Y, Xu D, Liao MM, Sun Y, Bao WD, Yao F
and Ma L: Barriers and opportunities in pancreatic cancer
immunotherapy. NPJ Precis Oncol. 8(199)2024.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Olaoba OT, Yang M, Adelusi TI, Maidens T,
Kimchi ET, Staveley-O'Carroll KF and Li G: Targeted therapy for
highly desmoplastic and immunosuppressive tumor microenvironment of
pancreatic ductal adenocarcinoma. Cancers (Basel).
16(1470)2024.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Reader CS, Vallath S, Steele CW, Haider S,
Brentnall A, Desai A, Moore KM, Jamieson NB, Chang D, Bailey P, et
al: The integrin αvβ6 drives pancreatic cancer through diverse
mechanisms and represents an effective target for therapy. J
Pathol. 249:332–342. 2019.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Yang D, Tang Y, Fu H, Xu J, Hu Z, Zhang Y
and Cai Q: Integrin β1 promotes gemcitabine resistance in
pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
Biochem Biophys Res Commun. 505:215–221. 2018.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Kim H, Huh S, Park J, Han Y, Ahn KG, Noh
Y, Lee SJ, Chu H, Kim SS, Jung HS, et al: Development of a
fit-for-purpose multi-marker panel for early diagnosis of
pancreatic ductal adenocarcinoma. Mol Cell Proteomics.
23(100824)2024.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Bukys T, Kurlinkus B, Sileikis A and
Vitkus D: The prospect of improving pancreatic cancer diagnostic
capabilities by implementing blood biomarkers: A study of
evaluating properties of a single IL-8 and in conjunction with
CA19-9, CEA, and CEACAM6. Biomedicines. 12(2344)2024.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Sivapalan L, Kocher HM, Ross-Adams H and
Chelala C: The molecular landscape of pancreatic ductal
adenocarcinoma. Pancreatology. 22:925–936. 2022.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Sivapalan L, Thorn GJ, Gadaleta E, Kocher
HM, Ross-Adams H and Chelala C: Longitudinal profiling of
circulating tumour DNA for tracking tumour dynamics in pancreatic
cancer. BMC Cancer. 22(369)2022.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Davidson C, Taggart D, Sims AH, Lonergan
DW, Canel M and Serrels A: FAK promotes stromal PD-L2 expression
associated with poor survival in pancreatic cancer. Br J Cancer.
127:1893–1905. 2022.PubMed/NCBI View Article : Google Scholar
|
|
160
|
S S KD, Joga R, Srivastava S, Nagpal K,
Dhamija I, Grover P and Kumar S: Regulatory landscape and
challenges in CAR-T cell therapy development in the US, EU, Japan,
and India. Eur J Pharm Biopharm. 201(114361)2024.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Sainatham C, Yadav D, Dilli Babu A,
Tallapalli JR, Kanagala SG, Filippov E, Murillo Chavez F, Ahmed N
and Lutfi F: The current socioeconomic and regulatory landscape of
immune effector cell therapies. Front Med (Lausanne).
11(1462307)2024.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Singhi AD, Koay EJ, Chari ST and Maitra A:
Early detection of pancreatic cancer: Opportunities and challenges.
Gastroenterology. 156:2024–2040. 2019.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Costa-Silva B, Aiello NM, Ocean AJ, Singh
S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, et
al: Pancreatic cancer exosomes initiate pre-metastatic niche
formation in the liver. Nat Cell Biol. 17:816–826. 2015.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Gebauer F, Wicklein D, Horst J, Sundermann
P, Maar H, Streichert T, Tachezy M, Izbicki JR and Bockhorn M:
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)
in pancreatic adenocarcinoma: an independent prognostic marker and
potential target for immunotherapy. Ann Surg Oncol. 21:2329–2337.
2014.
|
|
165
|
Zeltz C, Lu N and Gullberg D: Integrin
α11β1: A major collagen receptor on fibroblastic cells. Adv Exp Med
Biol. 819:73–83. 2014.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Brümmer J, Ebrahimnejad A, Flayeh R,
Schumacher U, Löning T, Bamberger AM and Wagener C: cis Interaction
of the cell adhesion molecule CEACAM1 with integrin beta(3). Am J
Pathol. 159:537–546. 2001.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Vuijk FA, van Beijnum JR, Cleuren ACA,
Bovenschen N, van Hinsbergh VWM and Griffioen AW: Co-expression of
CEACAM5 with integrins in pancreatic ductal adenocarcinoma and
surrounding stroma: Association with fibrosis and lipid raft
signaling. Cancers. 12(2857)2020.DOI: 10.3390/cancers12102857.
|
